Eladocagene exuparvovec (UpstazaTM). HTA ID: 22072
Upstaza™ is indicated for the treatment of patients aged 18 months and older with a clinical, molecular, and genetically confirmed diagnosis of aromatic L-amino acid decarboxylase (AADC) deficiency with a severe phenotype.
| NCPE Assessment Process | Complete |
| Rapid review commissioned | 06/12/2022 |
| Rapid review completed | 23/12/2022 |
| Rapid Review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of eladocagene exuparvovec compared with the current standard of care. |